Priming and boosting determinants on the antibody response to an Epidermal Growth Factor-based cancer vaccine

Pedro C. Rodriguez; Ileana Gonzalez; Adys Gonzalez; Janet Avellanet; Armando Lopez; Rolando Perez; Agustin Lage; Enrique Montero

doi:10.1016/j.vaccine.2008.07.003

Priming and boosting determinants on the antibody response to an Epidermal Growth Factor-based cancer vaccine

Pedro C. Rodriguez
, Ileana Gonzalez
, Adys Gonzalez
, Janet Avellanet
, Armando Lopez
, Rolando Perez
, Agustin Lage
, Enrique Montero

National School of Public Health

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Abstract

Epidermal Growth Factor chemically conjugated to P64k carrier protein from Neisseria meningitidis emulsified in Montanide ISA 51 adjuvant is a cancer vaccine under clinical evaluation. We explored the influence of priming and boosting variables on the antibody response in mice. An apparently low dose fractionated in multiple anatomical sites at priming accelerated the induction and enhanced the maximal antibody response, with a long-lasting effect. Moreover, shortening the boosting time reduces the antibody persistence. Repeatedly boosting shift subjects to good antibody-responders, maintaining the epitope immunodominance. We conclude that optimizing immunopharmacological determinants contribute to an earlier, stronger and prolonged anti-EGF antibody persistence.

Original language	English
Pages (from-to)	4647-4654
Number of pages	8
Journal	Vaccine
Volume	26
Issue number	36
DOIs	https://doi.org/10.1016/j.vaccine.2008.07.003
State	Published - 26 Aug 2008
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Boosting
EGF
Priming

Access to Document

10.1016/j.vaccine.2008.07.003

Cite this

@article{66c0fcd5d6f5420f9f988e579e730562,

title = "Priming and boosting determinants on the antibody response to an Epidermal Growth Factor-based cancer vaccine",

abstract = "Epidermal Growth Factor chemically conjugated to P64k carrier protein from Neisseria meningitidis emulsified in Montanide ISA 51 adjuvant is a cancer vaccine under clinical evaluation. We explored the influence of priming and boosting variables on the antibody response in mice. An apparently low dose fractionated in multiple anatomical sites at priming accelerated the induction and enhanced the maximal antibody response, with a long-lasting effect. Moreover, shortening the boosting time reduces the antibody persistence. Repeatedly boosting shift subjects to good antibody-responders, maintaining the epitope immunodominance. We conclude that optimizing immunopharmacological determinants contribute to an earlier, stronger and prolonged anti-EGF antibody persistence.",

keywords = "Boosting, EGF, Priming",

author = "Rodriguez, \{Pedro C.\} and Ileana Gonzalez and Adys Gonzalez and Janet Avellanet and Armando Lopez and Rolando Perez and Agustin Lage and Enrique Montero",

year = "2008",

month = aug,

day = "26",

doi = "10.1016/j.vaccine.2008.07.003",

language = "English",

volume = "26",

pages = "4647--4654",

journal = "Vaccine",

issn = "0264-410X",

number = "36",

}

TY - JOUR

T1 - Priming and boosting determinants on the antibody response to an Epidermal Growth Factor-based cancer vaccine

AU - Rodriguez, Pedro C.

AU - Gonzalez, Ileana

AU - Gonzalez, Adys

AU - Avellanet, Janet

AU - Lopez, Armando

AU - Perez, Rolando

AU - Lage, Agustin

AU - Montero, Enrique

PY - 2008/8/26

Y1 - 2008/8/26

N2 - Epidermal Growth Factor chemically conjugated to P64k carrier protein from Neisseria meningitidis emulsified in Montanide ISA 51 adjuvant is a cancer vaccine under clinical evaluation. We explored the influence of priming and boosting variables on the antibody response in mice. An apparently low dose fractionated in multiple anatomical sites at priming accelerated the induction and enhanced the maximal antibody response, with a long-lasting effect. Moreover, shortening the boosting time reduces the antibody persistence. Repeatedly boosting shift subjects to good antibody-responders, maintaining the epitope immunodominance. We conclude that optimizing immunopharmacological determinants contribute to an earlier, stronger and prolonged anti-EGF antibody persistence.

AB - Epidermal Growth Factor chemically conjugated to P64k carrier protein from Neisseria meningitidis emulsified in Montanide ISA 51 adjuvant is a cancer vaccine under clinical evaluation. We explored the influence of priming and boosting variables on the antibody response in mice. An apparently low dose fractionated in multiple anatomical sites at priming accelerated the induction and enhanced the maximal antibody response, with a long-lasting effect. Moreover, shortening the boosting time reduces the antibody persistence. Repeatedly boosting shift subjects to good antibody-responders, maintaining the epitope immunodominance. We conclude that optimizing immunopharmacological determinants contribute to an earlier, stronger and prolonged anti-EGF antibody persistence.

KW - Boosting

KW - EGF

KW - Priming

UR - https://www.scopus.com/pages/publications/48849094983

U2 - 10.1016/j.vaccine.2008.07.003

DO - 10.1016/j.vaccine.2008.07.003

M3 - Article

C2 - 18640164

AN - SCOPUS:48849094983

SN - 0264-410X

VL - 26

SP - 4647

EP - 4654

JO - Vaccine

JF - Vaccine

IS - 36

ER -

Priming and boosting determinants on the antibody response to an Epidermal Growth Factor-based cancer vaccine

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this